BR112015019590A2 - derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv - Google Patents
derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hivInfo
- Publication number
- BR112015019590A2 BR112015019590A2 BR112015019590A BR112015019590A BR112015019590A2 BR 112015019590 A2 BR112015019590 A2 BR 112015019590A2 BR 112015019590 A BR112015019590 A BR 112015019590A BR 112015019590 A BR112015019590 A BR 112015019590A BR 112015019590 A2 BR112015019590 A2 BR 112015019590A2
- Authority
- BR
- Brazil
- Prior art keywords
- hiv
- alkyl
- treatment
- acid derivatives
- betulinic acid
- Prior art date
Links
- -1 alkenyl modified betulinic acid derivatives Chemical class 0.000 title abstract 3
- 125000000217 alkyl group Chemical group 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 6
- 208000030507 AIDS Diseases 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000035800 maturation Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361768630P | 2013-02-25 | 2013-02-25 | |
| PCT/US2014/017688 WO2014130810A1 (en) | 2013-02-25 | 2014-02-21 | C-3 alkyl and alkenyl modified betulinic acid derivatives useful in the treatment of hiv |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015019590A2 true BR112015019590A2 (pt) | 2017-07-18 |
Family
ID=50288267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015019590A BR112015019590A2 (pt) | 2013-02-25 | 2014-02-21 | derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9249180B2 (enExample) |
| EP (1) | EP2958930A1 (enExample) |
| JP (1) | JP6186012B2 (enExample) |
| KR (1) | KR20150121712A (enExample) |
| CN (1) | CN105102468A (enExample) |
| AR (1) | AR094876A1 (enExample) |
| AU (1) | AU2014218754B2 (enExample) |
| BR (1) | BR112015019590A2 (enExample) |
| CA (1) | CA2902513A1 (enExample) |
| EA (1) | EA027861B1 (enExample) |
| IL (1) | IL240739A0 (enExample) |
| MX (1) | MX2015010354A (enExample) |
| SG (1) | SG11201506445PA (enExample) |
| TW (1) | TW201444862A (enExample) |
| WO (1) | WO2014130810A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016127074A1 (en) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
| WO2016168447A1 (en) * | 2015-04-14 | 2016-10-20 | VIIV HEALTHCARE (No.4) LIMITED | Methods of producing an hiv maturation inhibitor |
| EP3371171B1 (en) | 2015-11-02 | 2023-10-25 | Blueprint Medicines Corporation | Inhibitors of ret |
| AR107512A1 (es) | 2016-02-04 | 2018-05-09 | VIIV HEALTHCARE UK Nº 5 LTD | Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1 |
| WO2017161269A1 (en) | 2016-03-17 | 2017-09-21 | Blueprint Medicines Corporation | Inhibitors of ret receptor tyrosine kinases |
| US10227329B2 (en) | 2016-07-22 | 2019-03-12 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| US10035789B2 (en) | 2016-07-27 | 2018-07-31 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| WO2018044838A1 (en) * | 2016-08-31 | 2018-03-08 | Viiv Healthcare Company | Combinations and uses and treatments thereof |
| WO2019055119A1 (en) | 2017-09-14 | 2019-03-21 | Phoenix Biotechnology, Inc. | METHOD AND COMPOSITION FOR TREATING VIRAL INFECTION |
| CN106749486A (zh) * | 2016-11-30 | 2017-05-31 | 沈阳化工大学 | 一种以乙二胺为连接臂的齐墩果酸衍生物及其应用 |
| MX2020002884A (es) | 2017-09-14 | 2020-10-05 | Phoenix Biotechnology Inc | Método y composición neuroprotectora mejorada para tratar afecciones neurológicas. |
| BR112020020273A2 (pt) | 2018-04-03 | 2021-04-06 | Blueprint Medicines Corporation | Inibidor de ret para uso no tratamento de câncer tendo uma alteração de ret |
| US12275712B2 (en) | 2019-02-11 | 2025-04-15 | Hetero Labs Limited | Triterpene derivatives as HIV inhibitors |
| CN111362923A (zh) * | 2020-03-25 | 2020-07-03 | 魏威 | 制备ret抑制剂普拉塞替尼的方法、以及普拉塞替尼的中间体及其制备方法 |
| CN111440151A (zh) * | 2020-03-25 | 2020-07-24 | 魏威 | 制备抗肿瘤药普拉赛替尼的方法 |
| RU2020130238A (ru) | 2020-03-31 | 2022-03-14 | Феникс Байотекнолоджи, Инк. | Способ и композиции для лечения коронавирусной инфекции |
| EP4009981B1 (en) | 2020-03-31 | 2023-08-16 | Phoenix Biotechnology, Inc. | Method and compositions for treating coronavirus infection |
| EP4157829A1 (en) | 2020-05-29 | 2023-04-05 | Blueprint Medicines Corporation | Solid forms of pralsetinib |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5413999A (en) | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| US5679828A (en) | 1995-06-05 | 1997-10-21 | Biotech Research Labs, Inc. | Betulinic acid and dihydrobetulinic acid derivatives and uses therefor |
| US6369101B1 (en) * | 1999-02-26 | 2002-04-09 | Regents Of The University Of Minnesota | Therapeutic method to treat herpes virus infection |
| US20020137755A1 (en) | 2000-12-04 | 2002-09-26 | Bilodeau Mark T. | Tyrosine kinase inhibitors |
| US20040110785A1 (en) | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| US7365221B2 (en) | 2002-09-26 | 2008-04-29 | Panacos Pharmaceuticals, Inc. | Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof |
| US7745625B2 (en) | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
| AU2005224260A1 (en) | 2004-03-17 | 2005-09-29 | Panacos Pharmaceuticals, Inc. | Pharmaceuticals salts of 3-O-(3',3'-dimethylsuccinyl) betulinic acid |
| TW200628161A (en) | 2004-11-12 | 2006-08-16 | Panacos Pharmaceuticals Inc | Novel betulin derivatives, preparation thereof and use thereof |
| US20110144069A1 (en) | 2006-10-16 | 2011-06-16 | Myriad Genetics, Incorporated | Compounds for treating viral infections |
| AU2009214779A1 (en) | 2008-02-14 | 2009-08-20 | Virochem Pharma Inc. | Novel 17beta lupane derivatives |
| US9067966B2 (en) | 2009-07-14 | 2015-06-30 | Hetero Research Foundation, Hetero Drugs Ltd. | Lupeol-type triterpene derivatives as antivirals |
| ES2548905T3 (es) | 2010-06-04 | 2015-10-21 | Bristol-Myers Squibb Company | Amidas C-28 de derivados del ácido betulínico C-3 modificados como inhibidores de la maduración del VIH |
| EP2576585B8 (en) | 2010-06-04 | 2016-12-21 | VIIV Healthcare UK (No.5) Limited | Modified c-3 betulinic acid derivatives as hiv maturation inhibitors |
| SI2670764T1 (sl) | 2011-01-31 | 2016-03-31 | Bristol-Myers Squibb Company | C-28 amini derivatov c-3 modificirane betulinske kisline inhibitorjev zorenja hiv |
| CA2826113C (en) | 2011-01-31 | 2018-09-04 | Bristol-Myers Squibb Company | C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity |
| US8889854B2 (en) | 2012-05-07 | 2014-11-18 | Bristol-Myers Squibb Company | C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity |
-
2014
- 2014-02-21 CN CN201480010426.3A patent/CN105102468A/zh active Pending
- 2014-02-21 SG SG11201506445PA patent/SG11201506445PA/en unknown
- 2014-02-21 CA CA2902513A patent/CA2902513A1/en not_active Abandoned
- 2014-02-21 BR BR112015019590A patent/BR112015019590A2/pt not_active Application Discontinuation
- 2014-02-21 JP JP2015558996A patent/JP6186012B2/ja not_active Expired - Fee Related
- 2014-02-21 MX MX2015010354A patent/MX2015010354A/es unknown
- 2014-02-21 US US14/186,533 patent/US9249180B2/en not_active Expired - Fee Related
- 2014-02-21 AU AU2014218754A patent/AU2014218754B2/en not_active Ceased
- 2014-02-21 KR KR1020157026070A patent/KR20150121712A/ko not_active Withdrawn
- 2014-02-21 WO PCT/US2014/017688 patent/WO2014130810A1/en not_active Ceased
- 2014-02-21 EP EP14710687.6A patent/EP2958930A1/en not_active Withdrawn
- 2014-02-21 EA EA201591545A patent/EA027861B1/ru not_active IP Right Cessation
- 2014-02-24 AR ARP140100580A patent/AR094876A1/es unknown
- 2014-02-24 TW TW103106131A patent/TW201444862A/zh unknown
-
2015
- 2015-08-20 IL IL240739A patent/IL240739A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20140243298A1 (en) | 2014-08-28 |
| JP2016509062A (ja) | 2016-03-24 |
| AU2014218754A1 (en) | 2015-10-15 |
| EP2958930A1 (en) | 2015-12-30 |
| WO2014130810A1 (en) | 2014-08-28 |
| IL240739A0 (en) | 2015-10-29 |
| US9249180B2 (en) | 2016-02-02 |
| AU2014218754B2 (en) | 2017-04-20 |
| TW201444862A (zh) | 2014-12-01 |
| CN105102468A (zh) | 2015-11-25 |
| AR094876A1 (es) | 2015-09-02 |
| KR20150121712A (ko) | 2015-10-29 |
| SG11201506445PA (en) | 2015-09-29 |
| MX2015010354A (es) | 2015-10-09 |
| JP6186012B2 (ja) | 2017-08-23 |
| EA027861B1 (ru) | 2017-09-29 |
| EA201591545A1 (ru) | 2015-12-30 |
| CA2902513A1 (en) | 2014-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015019590A2 (pt) | derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv | |
| BR112014010105A2 (pt) | aminas de c-28 de derivados de ácido betulínico modificado por c-3 como inibidores de maturação de hiv | |
| BR112012030810A2 (pt) | "c-28 amidas de derivados de ácido c-3 betulínico modificados como inibidores de maturação de hiv" | |
| EA201391127A1 (ru) | C-17 и c-3 модифицированные тритерпеноиды с ингибиторной активностью созревания вич | |
| CY1121150T1 (el) | Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας | |
| EA201590450A1 (ru) | Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| ECSP14006132A (es) | Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih | |
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| BR112012030818A2 (pt) | "derivados de ácido c-3 betulínico modificado como inibidores da maturação do hiv" | |
| BR112015018491A2 (pt) | triterpenoides c-19-modificados com atividade inibidora de maturação de hiv | |
| BR112013023876A2 (pt) | derivados de pirroltriazinona como inibidores de pi3k | |
| UY32315A (es) | Compuestos de piperidina y usos de los mismo-596 | |
| BR112015016325A2 (pt) | Composto, composição farmacêutica, e, usos de uma composição, composto, pró-droga ou sal farmaceuticamente aceitável do mesmo | |
| MX2015017512A (es) | Compuestos 2,3-dihidrobenzofuran-5-ilicos como inhibidores de cinasas dyrk. | |
| CR20140144A (es) | Derivados de estra-1,3,5 (10), 16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos | |
| EA201591957A1 (ru) | Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения | |
| BR112014006559A2 (pt) | derivados do ácido betulínico com atividade antiviral | |
| CR20150007A (es) | Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos | |
| UY32055A (es) | Derivados sustituidos de la 5-Halo-N2-[sustituido](1-metil-1H-imidazol-4-il)pirimidin-2,-diamina y sus sales farmacéuticamente aceptables, procesos de preparación, composiciones y aplicaciones. | |
| MY199668A (en) | C-3 and c-17 modified triterpenoids as hiv-1 inhibitors | |
| UY32674A (es) | Derivados heterociclicos de la urea y sus metodos de empleo | |
| BR112014031969A2 (pt) | derivados de pirimidinona como agentes antimaláricos | |
| UY33723A (es) | ?COMPUESTOS Y SU USO PARA TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON Aß?. | |
| BR112015015250A2 (pt) | derivados de pirrolidina, composições farmacêuticas e usos dos mesmos | |
| UY32316A (es) | Derivados de piperidina utiles en el tratamiento de infecciones bacterianas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |